Myriad Genetics (MYGN) Liabilities and Shareholders Equity (2010 - 2026)

Myriad Genetics (MYGN) has 17 years of Liabilities and Shareholders Equity data on file, last reported at $673.7 million in Q1 2026.

• Liabilities and Shareholders Equity for Q1 2026 came in at $673.7 million, down 33.04% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.8 billion (down 33.68% YoY), and the FY2025 annual result was $706.6 million, down 31.24% from the prior year.
• Liabilities and Shareholders Equity fell to $673.7 million in Q1 2026 per MYGN's latest filing, from $706.6 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $1.3 billion in Q1 2022 and troughed at $673.7 million in Q1 2026.
• A 5-year average of $1.0 billion and a median of $1.1 billion in 2024 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2023 and 2025: Liabilities and Shareholders Equity declined 1.9% in 2023, then plunged 37.58% in 2025.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $1.2 billion in 2022, then retreated by 4.35% to $1.1 billion in 2023, then declined by 10.37% to $1.0 billion in 2024, then sank by 31.24% to $706.6 million in 2025, then slipped by 4.66% to $673.7 million in 2026.
• Business Quant data shows MYGN's Liabilities and Shareholders Equity at $673.7 million in Q1 2026, $706.6 million in Q4 2025, and $728.1 million in Q3 2025.